10月26日uSMART交易熱榜 | 近兩週累漲超20%,港股醫藥板塊“燃”起來了
10月26日uSMART交易熱度排行榜

港股自週一出現史詩級暴跌以來,交易熱度連續3日超過美股。港股的關注熱點集中在大盤指數ETF以及ATM等,而美股基本上是圍繞“老三樣”TQQQ、SQQQ、特斯拉在交易。
週三(26日)港股繼續反彈,看多港股的投資者進一步增加,兩倍做多恆科指ETF(7226)和盈富基金(2800)的排名衝到前2,要恭喜前一交易日勇敢抄底的投資者。騰訊、美團持續受到關注,其中騰訊捍衛住了200大關,昨日盤中還一度拉昇近6%,這幾日的成交額都在100億以上,較之前的兩位數明顯提升。
沉寂多時的港股醫藥板塊“燃”起來了,週三百濟神州、諾輝健康-B分別排在榜單第9、10,兩者近12個交易日累計漲幅分別爲28%、20%,近期政策預期向好,板塊景氣度提升,機構建議積極關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.